Skip to main content

Table 1 Folfiri-Cetuximab-regimen, to be repeated every 2 weeks

From: A phase II study for metabolic in vivo response monitoring with sequential 18FDG-PET-CT during treatment with the EGFR-monoclonal-antibody cetuximab in metastatic colorectal cancer: the Heidelberg REMOTUX trial

Chemotherapeutic agent

Dosage (mg/m2)

Treatment day

Cetuximab

250 *

1, 8

 

* 400 at first application

 

Irinotecan

180

1

Folinic Acid

400

1

5Fluorouracil (bolus)

400

1

5Fluorouracil (46 hours)

2400

1

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us